Literature DB >> 28588715

AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer.

Ahmed S K Al-Khafaji1,2, Michael W Marcus1, Michael P A Davies1, Janet M Risk1, Richard J Shaw1, John K Field1, Triantafillos Liloglou1.   

Abstract

Deregulation of mitotic spindle genes has been reported to contribute to the development and progression of malignant tumours. The aim of the present study was to explore the association between the expression profiles of Aurora kinases (AURKA, AURKB and AURKC), cytoskeleton-associated protein 5 (CKAP5), discs large-associated protein 5 (DLGAP5), kinesin-like protein 11 (KIF11), microtubule nucleation factor (TPX2), monopolar spindle 1 kinase (TTK), and β-tubulins (TUBB) and (TUBB3) genes and clinicopathological characteristics in human non-small cell lung carcinoma (NSCLC). Reverse transcription-quantitative polymerase chain reaction-based RNA gene expression profiles of 132 NSCLC and 44 adjacent wild-type tissues were generated, and Cox's proportional hazard regression was used to examine associations. With the exception of AURKC, all genes exhibited increased expression in NSCLC tissues. Of the 10 genes examined, only AURKA was significantly associated with prognosis in NSCLC. Multivariate Cox's regression analysis demonstrated that AURKA mRNA expression [hazard ratio (HR), 1.81; 95% confidence interval (CI), 1.16-2.84; P=0.009], age (HR, 1.03; 95% CI, 1.00-1.06; P=0.020), pathological tumour stage 2 (HR, 2.43; 95% CI, 1.16-5.10; P=0.019) and involvement of distal nodes (pathological node stage 2) (HR, 3.14; 95% CI, 1.24-7.99; P=0.016) were independent predictors of poor prognosis in patients with NSCLC. Poor prognosis of patients with increased AURKA expression suggests that those patients may benefit from surrogate therapy with AURKA inhibitors.

Entities:  

Keywords:  lung cancer; mRNA expression; mitotic spindle genes; prognosis

Year:  2017        PMID: 28588715      PMCID: PMC5452881          DOI: 10.3892/ol.2017.6012

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

Review 1.  CT screening for lung cancer: Is the evidence strong enough?

Authors:  J K Field; A Devaraj; S W Duffy; D R Baldwin
Journal:  Lung Cancer       Date:  2015-11-30       Impact factor: 5.705

2.  Aurora-C kinase supports mitotic progression in the absence of Aurora-B.

Authors:  Scott D Slattery; Michael A Mancini; Bill R Brinkley; Rebecca M Hall
Journal:  Cell Cycle       Date:  2009-09-21       Impact factor: 4.534

3.  A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.

Authors:  Humam Kadara; Carmen Behrens; Ping Yuan; Luisa Solis; Diane Liu; Xuemin Gu; John D Minna; J Jack Lee; Edward Kim; Waun-Ki Hong; Ignacio I Wistuba; Reuben Lotan
Journal:  Clin Cancer Res       Date:  2010-12-16       Impact factor: 12.531

4.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.

Authors:  Mitsuo Sato; Melville B Vaughan; Luc Girard; Michael Peyton; Woochang Lee; David S Shames; Ruben D Ramirez; Noriaki Sunaga; Adi F Gazdar; Jerry W Shay; John D Minna
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

Review 5.  Gene expression profiling of non-small-cell lung cancer.

Authors:  Ludovic Lacroix; Frédéric Commo; Jean-Charles Soria
Journal:  Expert Rev Mol Diagn       Date:  2008-03       Impact factor: 5.225

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 7.  Non-centrosomal TPX2-Dependent Regulation of the Aurora A Kinase: Functional Implications for Healthy and Pathological Cell Division.

Authors:  Georgina Garrido; Isabelle Vernos
Journal:  Front Oncol       Date:  2016-04-15       Impact factor: 6.244

8.  A novel five gene signature derived from stem-like side population cells predicts overall and recurrence-free survival in NSCLC.

Authors:  Deepak Perumal; Sandeep Singh; Sean J Yoder; Gregory C Bloom; Srikumar P Chellappan
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

9.  Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

Authors:  Eiji Ogawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Yosuke Otake; Yoshinobu Toda; Hirokazu Kotani; Toshiaki Manabe; Hiromi Wada; Fumihiro Tanaka
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

10.  Purposeful selection of variables in logistic regression.

Authors:  Zoran Bursac; C Heath Gauss; David Keith Williams; David W Hosmer
Journal:  Source Code Biol Med       Date:  2008-12-16
View more
  12 in total

1.  Serum-derived extracellular vesicles promote the growth and metastasis of non-small cell lung cancer by delivering the m6A methylation regulator HNRNPC through the regulation of DLGAP5.

Authors:  Shanshan Shi; Tong Wu; Zechen Ma; Xiudi Zhang; Ke Xu; Qi Tian; Liming Gao; Xiaobo Yin; Shufeng Xu; Shengbo Yang
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-29       Impact factor: 4.322

2.  Overexpression of HURP mRNA in head and neck carcinoma and association with in vitro response to vinorelbine.

Authors:  Ahmed S K Al-Khafaji; Paschalia Pantazi; Amelia Acha-Sagredo; Andrew Schache; Janet M Risk; Richard J Shaw; Triantafillos Liloglou
Journal:  Oncol Lett       Date:  2020-01-23       Impact factor: 2.967

3.  Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.

Authors:  X Zheng; J Chi; J Zhi; H Zhang; D Yue; J Zhao; D Li; Y Li; M Gao; J Guo
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

4.  Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells.

Authors:  Changjie Wu; Junfang Lyu; Eun Ju Yang; Yifan Liu; Baoyuan Zhang; Joong Sup Shim
Journal:  Nat Commun       Date:  2018-08-10       Impact factor: 14.919

5.  Differential expression of lung adenocarcinoma transcriptome with signature of tobacco exposure.

Authors:  Raneem Y Hammouz; Joanna K Kostanek; Aleksandra Dudzisz; Piotr Witas; Magdalena Orzechowska; Andrzej K Bednarek
Journal:  J Appl Genet       Date:  2020-06-20       Impact factor: 3.240

6.  Identification of key genes and biological pathways in Chinese lung cancer population using bioinformatics analysis.

Authors:  Ping Liu; Hui Li; Chunfeng Liao; Yuling Tang; Mengzhen Li; Zhouyu Wang; Qi Wu; Yun Zhou
Journal:  PeerJ       Date:  2022-01-31       Impact factor: 2.984

7.  Identification of key genes associated with progression and prognosis for lung squamous cell carcinoma.

Authors:  Xiaohan Ma; Huijun Ren; Ruoyu Peng; Yi Li; Liang Ming
Journal:  PeerJ       Date:  2020-05-06       Impact factor: 2.984

8.  Influence of gene expression on survival of clear cell renal cell carcinoma.

Authors:  Anders Berglund; Ernest K Amankwah; Young-Chul Kim; Philippe E Spiess; Wade J Sexton; Brandon Manley; Hyun Y Park; Liang Wang; Jad Chahoud; Ratna Chakrabarti; Chang D Yeo; Hung N Luu; Giuliano D Pietro; Alexander Parker; Jong Y Park
Journal:  Cancer Med       Date:  2020-09-28       Impact factor: 4.452

9.  Multi-omics analysis identifies potential mechanisms of AURKB in mediating poor outcome of lung adenocarcinoma.

Authors:  Jie Huang; Qianyun Zhang; Juan Shen; Xueqin Chen; Shenglin Ma
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

10.  Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance.

Authors:  Noushin Miralaei; Ahmad Majd; Kamran Ghaedi; Maryam Peymani; Masoomeh Safaei
Journal:  Cancer Med       Date:  2021-08-01       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.